ImmunoGen, Millennium extend agreement for tumor-activated prodrug

By Lisa Kerner

Erie, Pa., March 30 - ImmunoGen, Inc. and Millennium Pharmaceuticals, Inc. have extended the agreement giving Millennium certain rights to test ImmunoGen's tumor-activated prodrug technology with antibodies to specific targets.

ImmunoGen also maintains the right to license the technology for product development.

The agreement, scheduled to expire March 30, will now expire on March 30, 2007.

ImmunoGen, Inc., located in Cambridge, Mass., develops targeted anticancer biopharmaceuticals.

Millennium is a biopharmaceutical company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.